Gjc2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Gap Junction Protein Gamma 2 is encoded by the GJC2 gene located on chromosome 6q22.31. This gene encodes connexin 46.2 (Cx46.2), a gap junction protein belonging to the connexin family. Gap junctions allow direct cell-to-cell communication by forming channels that permit passage of ions, small metabolites, and signaling molecules. GJC2 is expressed predominantly in the central nervous system and peripheral glia, where it plays critical roles in oligodendrocyte function, myelination, and astrocyte coupling. Mutations in GJC2 cause Pelizaeus-Merzbacher-like disease (PMLD), a hypomyelinating leukodystrophy. [1]
| Gene Symbol | GJC2 |
|---|---|
| Full Name | Gap Junction Protein Gamma 2 (Connexin 46.2) |
| Chromosome | 6q22.31 |
| NCBI Gene ID | 57112 |
| OMIM | 608803 |
| Ensembl ID | ENSG00000146070 |
| UniProt ID | Q9NZA1 |
| Protein Length | 440 amino acids |
| Molecular Weight | 42.8 kDa |
Connexin 46.2 has the characteristic connexin structure:
Six connexin proteins oligomerize to form a hemichannel (connexon), and two hemichannels dock to form a gap junction channel.
GJC2/Cx46.2 performs essential gap junction functions:
GJC2 shows glial-specific expression:
| Disease | Mechanism | Evidence |
|---|---|---|
| Pelizaeus-Merzbacher-like disease (PMLD) | Hypomorphic mutations cause severe hypomyelinization | OMIM 608803 |
| Primary Lymphedema | Lymphatic vessel dysfunction | Mutations in GJC2 |
| Refsum Disease | Possible modifier | Genetic studies |
| Multiple Sclerosis | Potential role in demyelination | Expression studies |
| ALS | Astrocyte gap junction dysfunction | Animal models |
GJC2 is essential for proper myelination:
GJC2 as a therapeutic target:
Gjc2 knockout mice exhibit:
The study of Gjc2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.